Q1 2025 · 13F-HR
Sarissa Capital Management LPholdings as filed
Filed 2025-05-15 · accession 0000899140-25-000705
$154.7M
Reported value
7
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 45781M101 | INVA | INNOVIVA INC | $51.1M | 33.0% | 2,816,022 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $34.2M | 22.1% | 309,116 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $24.1M | 15.6% | 600,000 | Common | SOLE |
| 46333X108 | IRWD | IRONWOOD PHARMACEUTICALS INC | $24.1M | 15.6% | 16,390,000 | Common | SOLE |
| 023111206 | — | AMARIN CORP PLC | $11.1M | 7.20% | 24,850,623 | Common | SOLE |
| 516544103 | LNTH | LANTHEUS HLDGS INC | $9.8M | 6.31% | 100,000 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $364,501 | 0.24% | 508,016 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.